Drug Trial Radar · NCT04524273
Myasthenia Gravis Inebilizumab Trial
Last checked: Nov 20, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
238
Actual
Start
Oct 15, 2020
Primary completion
May 28, 2024
Study completion Jun 7, 2029
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Aug 24, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Randomized, double-blind, placebo-controlled, Phase 3, parallel-group study with optional open-label extension.
Conditions
- Myasthenia Gravis
Interventions
inebilizumabDrug
Participants will receive IV inebilizumab
IV PlaceboDrug
Participants will receive IV placebo matched to inebilizumab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline at Week 26 in Myasthenia Gravis Activities of Daily Living (MG-ADL) Score in the Overall Study PopulationTime frame: Baseline and Week 26
Locations
104 sites in 19 countries. Site status is shown where the registry gives one.
Viela Bio Investigative Site - 1015
Orange, California
Viela Bio Investigative Site - 1002
New Haven, Connecticut
Viela Bio Investigative Center - 1024
Washington D.C., District of Columbia
Viela Bio Investigative Site - 1005
Tampa, Florida
Viela Bio Investigative Site - 1012
Kansas City, Kansas
Viela Bio Investigative Site - 1018
Charlotte, North Carolina
Viela Bio Investigative Site - 1025
Canton, Ohio
Viela Bio Investigative Site - 1001
Cincinnati, Ohio
Viela Bio Investigative Site - 1009
Columbus, Ohio
Viela Bio Investigative Site - 1008
Pittsburgh, Pennsylvania
Viela Bio Investigative Site - 1019
Austin, Texas
Viela Bio Investigative Site - 1003
Houston, Texas
Viela Bio Investigative Site - 1014
San Antonio, Texas
Viela Bio Investigative Site - 1017
Salt Lake City, Utah
Viela Bio Investigative Site - 1004
Burlington, Vermont
Viela Bio Investigative Site - 1006
Richmond, Virginia
Viela Bio Investigative Site - 2001
Buenos Aires, Argentina
VielaBio Investigative Site - 2002
Buenos Aires, Argentina
Viela Bio Investigative Site - 2003
Buenos Aires, Argentina
Viela Bio Investigative Site - 5203
Grodno, Belarus
Viela Bio Investigative Site - 5204
Minsk, Belarus
Viela Bio Investigative Site - 5201
Vitebsk, Belarus
VielaBio Investigative Site - 2201
Porto Alegre, Brazil
VielaBio Investigative Site - 2203
Porto Alegre, Brazil
VielaBio Investigative Site - 2207
Ribeirão Preto, Brazil
VielaBio Investigative Site - 2206
São Paulo, Brazil
Viela Bio Investigative Site - 2205
São Paulo, Brazil
Viela Bio Investigative Site - 1102
Toronto, Ontario, Canada
Viela Bio Investigative Site - 1101
Montreal, Quebec, Canada
Viela Bio Investigative Site - 1103
Montreal, Quebec, Canada
Viela Bio Investigative Site 4009
Beijing, China
Viela Bio Investigative Site - 4007
Beijing, China
Viela Bio Investigative Site 4003
Beijing, China
Viela Bio Investigative Site - 4005
Guiyang, China
Viela Bio Investigative site 4010
Hunan, China
Viela Bio Investigative Site - 4011
Jinan, China
Viela Bio Investigative Site - 4006
Shanghai, China
Viela Bio Investigative Site - 4008
Suzhou, China
Viela Bio Investigative Site - 4004
Tianjin, China
Viela Bio Investigative Site 4012
Xi'an, China
Showing 40 of 104 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.